Wafik El-Deiry: Great discussion at WIN Consortium International Molecular Tumor Board
Wafik El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared a post on LinkedIn:
“Great discussion at today’s WIN Consortium in cancer personalized medicine International Molecular Tumor Board about young patient with stage IV colorectal cancer, germline MSH2 and multiple driver mutations including PIK3CA, PTEN, beta-catenin, p53, FBXW7, SMARCB1 among others.
Several good options for combination therapy as well as clinical trials were discussed.”
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.
He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023